Active	Status	Sponsor type	Region	Phase	Filter
1 Active 0 Inactive 1 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
AL008 / Alector
NCT05245916: IBI397 or Combination Therapies in Patients With Advanced Malignancies	Withdrawn	1a/1b	30	RoW	IBI397, IBI397+Sintilimab, IBI397+Rituximab	Innovent Biologics (Suzhou) Co. Ltd.	Advanced Malignancies	08/23	08/23